TriSalus Life Sciences, Inc. (NASDAQ:TLSIW – Get Free Report)’s stock price fell 2.9% during trading on Wednesday . The stock traded as low as $1.01 and last traded at $1.02. 9,044 shares were traded during trading, an increase of 167% from the average session volume of 3,385 shares. The stock had previously closed at $1.05.
TriSalus Life Sciences Stock Performance
The stock’s fifty day moving average is $1.09 and its two-hundred day moving average is $1.21.
Institutional Investors Weigh In On TriSalus Life Sciences
An institutional investor recently bought a new position in TriSalus Life Sciences stock. Bluefin Capital Management LLC bought a new stake in TriSalus Life Sciences, Inc. (NASDAQ:TLSIW – Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 115,989 shares of the company’s stock, valued at approximately $189,000.
About TriSalus Life Sciences
TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.
Featured Articles
- Five stocks we like better than TriSalus Life Sciences
- The Most Important Warren Buffett Stock for Investors: His Own
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- Market Cap Calculator: How to Calculate Market Cap
- 3 Steel Stocks Soaring After Tariff Announcements
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Receive News & Ratings for TriSalus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriSalus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.